奥曲肽联合兰索拉唑治疗酒精性肝硬化合并上消化道出血的临床疗效分析-现代医学

奥曲肽联合兰索拉唑治疗酒精性肝硬化合并上消化道出血的临床疗效分析

单位：1. 盱眙县人民医院感染科, 江苏盱眙 211700;
2. 盱眙县人民医院普通外科, 江苏盱眙 211700

分类号：R575.2;R573.2

出版年·卷·期（页码）：2018·37·第九期（1045-1048）

摘要：

目的：探讨奥曲肽联合兰索拉唑治疗酒精性肝硬化合并上消化道出血的治疗效果。方法：以随机法将本院2010年1月至2017年12月期间收治的69例酒精性肝硬化合并上消化道出血患者分成两组：给予兰索拉唑治疗的34例患者作为对照组，予以奥曲肽+兰索拉唑治疗的35例患者作为治疗组，治疗1个疗程后观察、对比两组临床治疗效果。结果：予以不同药物后，治疗组有效率为97.14%（34/35），与对照组的76.47%（26/34）相比，差异有统计学意义（P<0.05）；对照组治疗后有7例发生不良反应，而治疗组仅有2例（P<0.05）；治疗组住院时长（6.50±1.50） d、止血时长（21.65±3.49） h、输血量（238.60±10.52） ml，与对照组的（10.65±1.68） d、（32.50±2.55） h、（432.55±12.68） ml相比，差异有统计学意义（P<0.05）。结论：临床联用奥曲肽与兰索拉唑治疗酒精性肝硬化合并上消化道出血可有效防治不良反应的发生，提高治疗效果，具有较高的临床推广价值。

Objective: To investigate the therapeutic effect of octreotide combined with lansoprazole on alcoholic liver cirrhosis with upper gastrointestinal bleeding. Methods: A total of 69 patients with alcoholic liver cirrhosis with upper gastrointestinal bleeding admitted to our hospital from January 2010 to December 2017 were divided into two groups:34 patients treated with lansoprazole as the control group, 35 patients treated with lansoprazole+octreotide as the treatment group, after a course of treatment, the clinical efficacy between the two groups were compared. Results: After treatment with different drugs, the effective rate of treatment in the treatment group was 97.14% (34/35), which was significantly different from that[76.47%, (26/34)] in the control group(P<0.05). After treatment, 7 patients developed adverse reactions in the treatment group, 2 patients developed adverse reactions in the control group (P<0.05). The length of hospitalization[(6.50±1.50) d], the duration of hemostasis[(21.65±3.49) h], the volume of blood transfusion[(238.60±10.52) ml] in the treatment group were significantly lower than those[(10.65±1.68) d, (32.50±2.55) h, (432.55±12.68) ml] in the control group, there were significant differences (P<0.05). Conclusion: The combination of octreotide and lansoprazole in the treatment of alcoholic liver cirrhosis with upper gastrointestinal bleeding can effectively prevent adverse reactions, improve the therapeutic effect, which has a high clinical promotion value.

参考文献：

[1] 邓淑凯.奥曲肽联合凝血酶治疗酒精性肝硬化合并上消化道出血的临床疗效观察[J].实用临床医药杂志,2015,19(13):111-112.
[2] 周筱燕,周岩芬,杨辉,等.奥曲肽分别与垂体后叶素和特利加压素联用对酒精性肝硬化合并上消化道出血患者实验室指标的影响研究[J].临床和实验医学杂志,2017,16(24):2451-2454.
[3] 丁敏,亢锴.奥曲肽治疗酒精性肝硬化合并上消化道出血的疗效和药物经济学评价[J].现代消化及介入诊疗,2016,21(1):14-16.
[4] NAKAMUR A,SATA M,SUZUKI K,et al.Open-labeled randomized controlled trial to compare diuretic therapy with recombinant human serum albumin and diuretic therapy for therapeutic treatment of ascites in patients with advanced liver cirrhosis:An exploratory trial[J].Hepatology Research,2014,44(5):502-514.
[5] 陈文林,郑小波.奥曲肽联合兰索拉唑治疗急性上消化道出血的疗效观察[J].中国急救医学,2014,11(21):59-60.
[6] 田邦妮,黄盖,陈五一,等.兰索拉唑、奥曲肽、血凝酶三药联用治疗老年急性上消化道出血疗效分析[J].现代中西医结合杂志,2015,26(6):613-615.
[7] 黄少辉,苏立勇.重症上消化道出血患者给予兰索拉唑凝血酶奥曲肽联合保守治疗效果观察[J].黑龙江医学,2017,41(11):1068-1069.
[8] LI H,WU J S,WANG X T,et al.Major hepatectomy is a safe modality for the treatment of intrahepatic cholangiocarcinoma in selected patients complicated with cirrhosis[J].Journal of Gastrointestinal Surgery,2014,18(1):194-199.
[9] 秦兴亚.兰索拉唑联合奥曲肽治疗酒精性肝硬化上消化道出血的效果观察[J].肝脏,2015,26(9):737-738.
[10] 何晓华.不同剂量兰索拉唑治疗急性非静脉曲张性上消化道出血的疗效观察[J].中国处方药,2017,15(12):103-104.
[11] 齐乐,陈洪.不同质子泵抑制剂与抗血小板药物联用时心血管安全性Meta分析[J].东南大学学报(医学版),2013,32(3):308-316.
[12] 刘伟,李珊珊,周磊,等.奥曲肽与垂体后叶素联合治疗酒精性肝硬化失代偿期第一次上消化道出血的临床观察[J].中华全科医学,2014,12(10):1678-1679.

服务与反馈：

【文章下载】【发表评论】【查看评论】【加入收藏】

提示：您还未登录，请登录！点此登录